Innovating Innovent

How Innovent will pursue its three-pronged pipeline strategy with $260M round

An oversubscribed $260 million series D round gives Innovent Biologics Inc. enough cash to submit BLAs for its three lead biosimilars in China, but don’t call it a biosimilars company. The Chinese biotech

Read the full 339 word article

User Sign In